Teva Pharmaceutical Industries announced the formation of a global pharma partnering research collaboration to create a comprehensive understanding and drive insights into neuroprotective therapeutic approaches in Huntington disease.
The pharma partnering brings together the field's leading scientific researchers from Singapore, the United Kingdom, Canada, Germany, United States and Israel in a coordinated and intense research program developed in Israel by Dr. Michael Hayden, one of the foremost experts on Huntington disease.
The focus of the pharma partnering program is the interaction between laquinimod, a neuroprotective agent currently being investigated in multiple sclerosis, and various molecular pathways operative in Huntington disease.
The collaboration consists of leading Huntington disease research centers and others, purposely selected for their expertise in specific pathways relevant to HD. They include:
Prof. Sarah Tabrizi, Professor of Clinical Neurology, University College London (UCL), Institute of Neurology
Dr. Mahmoud A. Pouladi, Translational Laboratory in Genetic Medicine (TLGM) at the National University of Singapore (NUS) and Biomedical Science Institutes (BMSI)
Prof. Ralf Gold, Department of Neurology, St. Josef Hospital/Ruhr University Bochum, Germany,
Dr. Blair Leavitt, Department of Medical Genetics, The University of British Colombia
Prof. Gareth John, Associate Professor Neurology, Mount Sinai School of Medicine
Prof. Daniel Offen, Director, the Neuroscience Laboratory at Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv university.
For further deal information visit Current Agreements (subscription required)
Read: more on Teva company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with Teva
Report: Huntington's Disease Partnering 2007-2013
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity